Secondary stroke prevention with drugs: Single or combined therapy?

Cerebrovascular Diseases

Volumn 9, Issue SUPPL. 3, 1999, Pages 24-28

  Van Gijn, J ^a   Algra, A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STROKE;

ANTICOAGULANTS; ASPIRIN; CEREBROVASCULAR DISORDERS; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; TICLOPIDINE;

EID: 0032813333     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047551     Document Type: Conference Paper

References (38)

1. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
2. Algra A, van Gijn J: Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996;60:197-199.
3. Warlow C: Secondary prevention of stroke. Lancet 1992;339:724-727.
4. Van Gijn J, Warlow CP, Norrving B: Low-dose aspirin and stroke. Stroke 1992;24:476-477.
5. Dyken ML, Barnett HJM, Easton JD, et al: Low-dose aspirin and stroke - 'It ain't necessarily so'. Stroke 1992;23:1395-1399.
6. Fields WS, Lemak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301-316.
7. Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-59.
8. Reuther R, Dorndorf W, Loew D: Behandlung transitorisch-ischämischer Attacken mit Azetylsalizylsäure. Münch Med Wochenschr 1980; 122:795-798.
9. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R: Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires. Résultats d'un essai thérapeutique contrôlé de 3 ans. Rev Neurol (Paris) 1982;138: 367-385.
10. Bousser MG, Eschwege E, Haguenau M, et al: 'AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983;14: 5-14.
11. Sorensen PS, Pedersen H, Marquardsen J, et al: Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke 1983;14:15-22.
12. Swedish Cooperative Study: High-dose acetylsalicylic acid after cerebral infarction. Stroke 1987;18:325-334.
13. Boysen G, Sorensen PS, Juhler M, Andersen AR, Boas J, Olsen JS, et al: Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke 1988;19:1211-1215.
14. The SALT Collaborative Group: Swedish Aspirin Low-Dose Trial (SALT); 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349.
15. UK-TIA Study Group: The United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial: Final results. J Neurol Neurosurg Psychiatry 1991;54:1044-1054.
16. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-1266.
17. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
18. European Stroke Prevention Study Group: European Stroke Prevention Study: Principal endpoints. Lancet 1987;ii:1351-1354.
19. Gent M, Blakely JA, Easton JD, et al: The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;i:1215-1220.
20. Hass WK, Easton JD, Adams HP, et al: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
21. Van Gijn J, Algra A: Ticlopidine, trials, and torture. Stroke 1994;25:1097-1098.
22. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
23. FitzGerald GA: Dipyridamole. N Engl J Med 1987;316:1247-1257.
24. The ESPS-2 Group: European Stroke Prevention Study 2: Efficacy and safety data. Secondary endpoints. J Neurol Sci 1997;151 (suppl):27-37.
25. American-Canadian Cooperative Study Group: Persantin aspirin trial in cerebral ischemia. II. Endpoint results. Stroke 1983;16: 406-415.
26. Kaye J: A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Boehringer Ingelheim Internal Report. Bracknell/Berks, Boehringer Ingelheim, 1990.
27. Major Ongoing Stroke Trials. Stroke 1997;28: 2104.
28. The Sixty-Plus Reinfarction Study Research Group: A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;ii: 989-994.
29. Smith P, Arnesen H, Holme I: The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323: 147-152.
30. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
31. The EPSIM Research Group: A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-708.
32. Jonas S: Anticoagulant therapy in cerebrovascular disease: A review and meta-analysis. Stroke 1988;19:1043-1048.
33. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342: 1255-1262.
34. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group: A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-865.
35. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E: A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239.
36. Van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J: Grading white matter lesions on CT and MRI: A simple scale. J Neurol Neurosurg Psychiatry 1990;53:1080-1083.
37. Pantoni L, Garcia JH: Pathogenesis of leukoaraiosis. A review. Stroke 1997;28:652-659.
38. Mohr JP and the WARSS Group: Design considerations for the Warfarin-Antiplatelet Recurrent Stroke Study. Cerebrovasc Dis 1995;5: 156-157.